In the last trading session, 1.1 million Omega Therapeutics Inc (NASDAQ:OMGA) shares changed hands as the company’s beta touched 1.83. With the company’s per share price at $1.39 changed hands at $0.32 or 29.91% during last session, the market valuation stood at $76.67M. OMGA’s last price was a discount, traded about -353.24% off its 52-week high of $6.30. The share price had its 52-week low at $0.89, which suggests the last value was 35.97% up since then. When we look at Omega Therapeutics Inc’s average trading volume, we note the 10-day average is 0.27 million shares, with the 3-month average coming to 199.62K.

Analysts gave the Omega Therapeutics Inc (OMGA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OMGA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Omega Therapeutics Inc’s EPS for the current quarter is expected to be -0.28.

Omega Therapeutics Inc (NASDAQ:OMGA) trade information

Instantly OMGA was in green as seen at the end of in last trading. With action 55.48%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -53.82%, with the 5-day performance at 55.48% in the green. However, in the 30-day time frame, Omega Therapeutics Inc (NASDAQ:OMGA) is 4.51% up. Looking at the short shares, we see there were 5.61 million shares sold at short interest cover period of 38.92 days.

The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 84.56% from its current market value. According to analyst projections, OMGA’s forecast low is 7 with 11 as the target high. To hit the forecast high, the stock’s price needs a -691.37% plunge from its current level, while the stock would need to soar -403.6% for it to hit the projected low.

Omega Therapeutics Inc (OMGA) estimates and forecasts

Data shows that the Omega Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -40.60% over the past 6 months, a 31.67% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach 122.70% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 1.24M. 6 analysts are of the opinion that Omega Therapeutics Inc’s revenue for the current quarter will be 1.24M. The company’s revenue for the corresponding quarters a year ago was 831k and 989k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 49.20%. The estimates for the next quarter sales put growth at 25.40%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -48.08%. The 2024 estimates are for Omega Therapeutics Inc earnings to increase by 37.06%.

OMGA Dividends

Omega Therapeutics Inc is expected to release its next quarterly earnings report in November.

Omega Therapeutics Inc (NASDAQ:OMGA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.62% of Omega Therapeutics Inc shares while 94.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.66%. There are 94.11% institutions holding the Omega Therapeutics Inc stock share, with FLAGSHIP PIONEERING INC. the top institutional holder. As of 2024-06-30, the company held 52.9924% of the shares, roughly 29.23 million OMGA shares worth $60.5 million.

FMR LLC holds the second largest percentage of outstanding shares, with 11.3181% or 6.24 million shares worth $12.92 million as of 2024-06-30.